Dr. Pedro M. Barata
Claim this profileTulane University Health Sciences Center
Studies Kidney Cancer
Studies Renal Cell Carcinoma
20 reported clinical trials
52 drugs studied
Area of expertise
1Kidney Cancer
Stage IV
PD-L1 positive
Stage III
2Renal Cell Carcinoma
Stage IV
Stage III
TFE-3/B translocation positive
Affiliated Hospitals
Clinical Trials Pedro M. Barata is currently running
Radium-223 + Cabozantinib
for Kidney Cancer with Bone Metastasis
This phase II trial studies whether adding radium-223 dichloride to the usual treatment, cabozantinib, improves outcomes in patients with renal cell cancer that has spread to the bone. Radioactive drugs such as radium-223 dichloride may directly target radiation to cancer cells and minimize harm to normal cells. Cabozantinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving radium-223 dichloride and cabozantinib may help lessen the pain and symptoms from renal cell cancer that has spread to the bone, compared to cabozantinib alone.
Recruiting1 award Phase 216 criteria
Cabozantinib +/− Atezolizumab
for Advanced Kidney Cancer
This phase II trial compares the effect of atezolizumab in combination with usual treatment with cabozantinib to cabozantinib alone in patients with papillary renal cell carcinoma that has spread from where it first started (primary site) to other places in the body (metastatic). Papillary renal cell carcinoma (PRCC) is a type of kidney cancer that forms in the lining of the tiny tubes in the kidney that return filtered substances that the body needs back to the blood and remove extra fluid and waste as urine. Most papillary tumors look like long, thin finger-like growths under a microscope. It is also called papillary kidney cancer or PRCC. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the tumor and may interfere with the ability of tumor cells to grow and spread. Cabozantinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals tumor cells to multiply and may also prevent the growth of new blood vessels that tumors need to grow. By these actions it may help slow or stop the spread of tumor cells. Combination therapy with atezolizumab and cabozantinib may shrink the tumor and allow a longer survival time in patients with metastatic renal cell carcinoma.
Recruiting1 award Phase 230 criteria
More about Pedro M. Barata
Clinical Trial Related1 year of experience running clinical trials · Led 20 trials as a Principal Investigator · 8 Active Clinical TrialsTreatments Pedro M. Barata has experience with
- Nivolumab
- Ipilimumab
- Cabozantinib
- Pembrolizumab
- Lenvatinib
- Prednisone
Breakdown of trials Pedro M. Barata has run
Kidney Cancer
Renal Cell Carcinoma
Prostate Cancer
Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Pedro M. Barata specialize in?
Pedro M. Barata focuses on Kidney Cancer and Renal Cell Carcinoma. In particular, much of their work with Kidney Cancer has involved Stage IV patients, or patients who are PD-L1 positive.
Is Pedro M. Barata currently recruiting for clinical trials?
Yes, Pedro M. Barata is currently recruiting for 7 clinical trials in New Orleans Louisiana. If you're interested in participating, you should apply.
Are there any treatments that Pedro M. Barata has studied deeply?
Yes, Pedro M. Barata has studied treatments such as Nivolumab, Ipilimumab, Cabozantinib.
What is the best way to schedule an appointment with Pedro M. Barata?
Apply for one of the trials that Pedro M. Barata is conducting.
What is the office address of Pedro M. Barata?
The office of Pedro M. Barata is located at: Tulane University Health Sciences Center, New Orleans, Louisiana 70112 United States. This is the address for their practice at the Tulane University Health Sciences Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.